Gregory Gordon, MD, JD
Chief Medical Officer
greg@sclerodermaresearch.org
Bio
Dr. Gregory Gordon joined the Scleroderma Research Foundation’s leadership team as Chief Medical Officer in 2024. As the CMO, Greg provides strategic leadership for the overall direction as well as the daily operations of the CONQUEST Platform Study. He additionally supports the SRF team’s community outreach and patient engagement activities. Greg has held multiple leadership roles in the biotech industry over the past fifteen years.
Greg is an internist and began his career working as a primary care physician at Harvard Vanguard Medical Associates in Boston. In 2008, he transitioned to a full-time position in the pharmaceutical industry. He has spent most of his career at local biotech companies, where he has been part of teams responsible for successfully bringing multiple treatments to patients, including linaclotide (Linzess™), darvadstrocel (Alofisel™), and setmelanotide (Imcivree™). Before joining SRF, Greg led a team of physicians overseeing the development of potential treatments for multiple neurologic and pediatric diseases at PTC Therapeutics.
Greg is a native of Larchmont, New York. Before attending medical school at the State University of New York, Stony Brook, he earned a JD from Columbia Law School and worked as an attorney in New York City. He now lives in Brookline, just outside of Boston, where he and his wife raise two sons.
